Gemin X Biotechnologies
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
400 Chesterfield Pkwy Ste 100, Malvern, ...Phone Number
(610) 640-5735Website
www.geminx.comRevenue
$6.7 MillionIndustry
About Gemin X Biotechnologies
Gemin X Biotechnologies Org Chart
Is Gemin X Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Gemin X Biotechnologies has new funding data
Gemin X Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Gemin X Biotechnologies recently announced quarterly report
Check out if Gemin X Biotechnologies is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Gemin X Biotechnologies
Click to see if Gemin X Biotechnologies had a recent Job posting/layoffs
Product Launch: Get notified when Gemin X Biotechnologies launches new products
Check if Gemin X Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Gemin X Biotechnologies
Find 3 more new buyers
Company Profile Activity
Activity Insights
Gemin X Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Gemin X Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Gemin X Biotechnologies.
Top Business Services Companies
Frequently Asked Questions Regarding Gemin X Biotechnologies
Gemin X Pharmaceuticals specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), a small molecule, pan Bcl-2 inhibitor, is currently in Phase 2 clinical trials in both hematological and solid tumor cancers. Gemin X's second compound GMX1777, is a potent, small molecule tha... Read More